Four things to know:
1. Xtant’s plan was submitted on May 3 and has been granted a plan period through October 4, 2020. The company did not outline its plan for compliance in its press release.
2. The firm’s common stock will still be listed on the NYSE through Oct. 4, 2020. Throughout that time, Xtant is subject to review to ensure the company is making progress.
3. Xtant’s shares of common stock could be delisted from the NYSE American if the company doesn’t make progress according to its plan.
4. Xtant focuses on surgical solutions for the treatment of spinal disorders.
More articles on orthopedic devices:
10 major updates from NuVasive in the last 6 months
Spine sales and revenue: How 10 companies performed in Q1
Medtronic reports 1.1% drop in Q4 spine revenue: 4 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
